c-Fos proteins, induced by the serotonin receptor agonist DOI, are not expressed in 5-HT2A positive cortical neurons

Molecular Brain Research

Volumn 71, Issue 2, 1999, Pages 358-363

  MaćKowiak, Marzena ^a   Chocyk, Agnieszka ^a   Fijał, Katarzyna ^a   Czyrak, Anna ^a   Wȩdzony, Krzysztof ^a  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

Author keywords

5 HT2A receptors; c Fos; DOI; Double labeling; Immunohistochemistry; Parietal cortex

Indexed keywords

4 IODO 2,5 DIMETHOXYAMPHETAMINE; PROTEIN C FOS; SEROTONIN 2A RECEPTOR; SEROTONIN AGONIST;

ANIMAL EXPERIMENT; ARTICLE; BRAIN CELL; DENDRITIC CELL; IMMUNOREACTIVITY; MALE; NONHUMAN; ONCOGENE C FOS; PARIETAL LOBE; PERIKARYON; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN LOCALIZATION; PYRAMIDAL NERVE CELL; RAT; TISSUE DISTRIBUTION;

AMPHETAMINES; ANIMALS; CEREBRAL CORTEX; MALE; MOLECULAR WEIGHT; NEURONS; PROTO-ONCOGENE PROTEINS C-FOS; RATS; RATS, WISTAR; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTOR, SEROTONIN, 5-HT2C; RECEPTORS, SEROTONIN; SEROTONIN AGONISTS;

ANIMALIA;

EID: 0344678347     PISSN: 0169328X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-328X(99)00195-3     Document Type: Article

References (35)

1. Abi-Saab W.M., Bubser M., Roth R.H., Deutch A.Y. 5-HT2 receptor regulation of extracellular GABA levels in the prefrontal cortex. Neuropsychopharmacology. 20:1999;92-96.
2. Abraham H.D., Aldridge A.M., Gogia P. The psychopharmacology of hallucinogens. Neuropsychopharmacology. 14:1996;285-298.
3. Aghajanian G.K., Marek G.J. Serotonin induces excitatory postsynaptic potentials in apical dendrites of neocortical pyramidal cells. Neuropharmacology. 36:1997;589-599.
4. 2A receptors, increases EPSCs in layer V pyramidal cells of prefrontal cortex by an asynchronous mode of glutamate release. Brain Res. 825:1999;161-171.
5. Baxter G., Kennett G., Blaney F., Blackburn T. 5-HT2 receptor subtypes: a family re-united? Trends. Pharmacol. Sci. 16:1995;105-110.
6. Berry S.A., Shah M.C., Khan N., Roth B.L. Rapid agonist-induced internalization of the 5-hydroxytryptamine2A receptor occurs via the endosome pathway in vitro. Mol. Pharmacol. 50:1996;306-313.
7. Chaudhuri A. Neural activity mapping with inducible transcription factors. NeuroReport. 8:1997;v-ix.
8. Conn P.J., Sanders-Bush E. Regulation of serotonin-stimulated phosphoinositide hydrolysis: relation to the serotonin 5-HT-2 binding site. J. Neurosci. 6:1986;3669-3675.
9. Dragunow M., Faull R. The use of c-fos as a metabolic marker in neuronal pathway tracing. J. Neurosci. Methods. 29:1989;261-265.
10. Fiorella D., Rabin R.A., Winter J.C. The role of the 5-HT2A and 5-HT2C receptors in the stimulus effects of hallucinogenic drugs: I. Antagonist correlation analysis. Psychopharmacology (Berlin). 121:1995;347-356.
11. Hamada S., Senzaki K., Hamaguchi-Hamada K., Tabuchi K., Yamamoto H., Yamamoto T., Yoshikawa S., Okano H., Okado N. Localization of 5-HT2A receptor in rat cerebral cortex and olfactory system revealed by immunohistochemistry using two antibodies raised in rabbit and chicken. Mol. Brain Res. 54:1998;199-211.
12. Herdegen T., Leah J.D. Inducible and constitutive transcription factors in the mammalian nervous system: control of gene expression by jun, fos and krox, and CREB/ATF proteins. Brain Res. Rev. 28:1998;370-490.
13. Huntley G.W., Vickers J.C., Janssen W., Brose N., Heinemann S.F., Morrison J.H. Distribution and synaptic localization of immunocytochemically identified NMDA receptor subunit proteins in sensory-motor and visual cortices of monkey and human. J. Neurosci. 14:1994;3603-3619.
14. Jakab R.L., Goldman-Rakic P.S. 5-Hydroxytryptamine2A serotonin receptors in the primate cerebral cortex: possible site of action of hallucinogenic and antipsychotic drugs in pyramidal cell apical dendrites. Proc. Natl. Acad. Sci. U.S.A. 95:1998;735-740.
15. Kehne J.H., Baron B.M., Carr A.A., Chaney S.F., Elands J., Feldman D.J., Frank R.A., van Giersbergen P.L., McCloskey T.C., Johnson M.P., McCarty D.R., Poirot M., Senyah Y., Siegel B.W., Widmaier C. Preclinical characterization of the potential of the putative atypical antipsychotic MDL 100,907 as a potent 5-HT2A antagonist with a favorable CNS safety profile. J. Pharmacol. Exp. Ther. 277:1996;968-981.
16. Kennett G.A., Curzon G. Potencies of antagonists indicate that 5-HT1C receptors mediate 1-3(chlorophenyl)piperazine-induced hypophagia. Br. J. Pharmacol. 103:1991;2016-2020.
17. Leslie R.A., Moorman J.M., Coulson A., Grahame Smith D.G. Serotonin2/1C receptor activation causes a localized expression of the immediate-early gene c-fos in rat brain: evidence for involvement of dorsal raphe nucleus projection fibres. Neuroscience. 53:1993;457-463.
18. Leslie R.A., Moorman J.M., Grahame-Smith D.G. Lithium enhances 5-HT2A receptor-mediated c-fos expression in rat cerebral cortex. NeuroReport. 5:1993;241-244.
19. Leysen J.E., Janssen P.F., Niemegeers C.J. Rapid desensitization and down-regulation of 5-HT2 receptors by DOM treatment. Eur. J. Pharmacol. 163:1989;145-149.
20. Marek G.J., Aghajanian G.K. LSD and the phenethylamine hallucinogen DOI are potent partial agonists at 5-HT2A receptors on interneurons in rat piriform cortex. J. Pharmacol. Exp. Ther. 278:1996;1373-1382.
21. Marek G.J., Aghajanian G.K. The electrophysiology of prefrontal serotonin systems: therapeutic implications for mood and psychosis. Biol. Psychiatry. 44:1998;1118-1127.
22. Moorman J.M., Grahame-Smith D.G., Smith S.E., Leslie R.A. Chronic electroconvulsive shock enhances 5-HT2 receptor-mediated head shakes but not brain c-fos induction. Neuropharmacology. 35:1996;303-313.
23. Pompeiano M., Palacios J.M., Mengod G. Distribution of the serotonin 5-HT2 receptor family mRNAs: comparison between 5-HT2A and 5-HT2C receptors. Mol. Brain Res. 23:1994;163-178.
24. Roth B.L. Multiple serotonin receptors: clinical and experimental aspects. Ann. Clin. Psychiatry. 6:1994;67-78.
25. Roth B.L., Palvimaki E.P., Berry S., Khan N., Sachs N., Uluer A., Choudhary M.S. 5-Hydroxytryptamine2A (5-HT2A) receptor desensitization can occur without down-regulation. J. Pharmacol. Exp. Ther. 275:1995;1638-1646.
26. Rouillard C., Bovetto S., Gervais J., Richard D. Fenfluramine-induced activation of the immediate-early gene c-fos in the striatum: possible interaction between serotonin and dopamine. Mol. Brain Res. 37:1996;105-115.
27. Tilakaratne N., Friedman E. Genomic responses to 5-HT1A or 5-HT2A/2C receptor activation is differentially regulated in four regions of rat brain. Eur. J. Pharmacol. 307:1996;211-217.
28. Tilakaratne N., Friedman E. Genomic responses to 5-HT1A or 5-HT2A/2C receptor activation is differentially regulated in four regions of rat brain. Eur. J. Pharmacol. 307:1996;211-217.
29. van Wijngaarden I., Tulp M.T., Soudijn W. The concept of selectivity in 5-HT receptor research. Eur. J. Pharmacol. 188:1990;301-312.
30. Wȩdzony K., Czyrak A. Competitive and non-competitive NMDA receptor antagonists induce c-Fos expression in the rat anterior, cingulate cortex. J. Physiol. Pharmacol. 47:1996;525-533.
31. Wȩdzony K., Czyrak A. The distribution of the NMDA R1 subunit in the rat hippocampus - an immunocytohistochemical study. Brain Res. 768:1997;333-337.
32. Willins D.L., Deutch A.Y., Roth B.L. Serotonin 5-HT2A receptors are expressed on pyramidal cells and interneurons in the rat cortex. Synapse. 27:1997;79-82.
33. Wright D.E., Seroogy K.B., Lundgren K.H., Davis B.M., Jennes L. Comparative localization of serotonin1A, 1C, and 2 receptor subtype mRNAs in rat brain. J. Comp. Neurol. 351:1995;357-373.
34. Wu C., Yoder E.J., Shih J., Chen K., Dias P., Shi L., Ji X.D., Wei J., Conner J.M., Kumar S., Ellisman M.H., Singh S.K. Development and characterization of monoclonal antibodies specific to the serotonin 5-HT2A receptor. J. Histochem. Cytochem. 46:1998;811-824.
35. Zifa E., Fillion G. 5-Hydroxytryptamine receptors. Pharmacol. Rev. 44:1992;401-458.